Strategic, Data-driven Feasibility
With skyrocketing development costs and expanding study timelines, determining the viability of a study is more crucial than ever. Traditional approaches of feasibility relied on site surveys and other unreliable methodology. Now PPD has shifted that ineffective paradigm to take advantage of analytics and external data sources to develop models that guide our innovative, strategic feasibility services. We're able to provide additional reliable information more quickly to guide site selection and recruitment planning, support protocol and trial optimization, and centralize country and site selection.
Watch the Webinar
PPD experts discuss data-driven feasibility
We merge data from patient, investigator and site perspectives to drive our recommendations. We use multiple data sources, including:
- PPD investigator, laboratory and clinical trial data
- De-identified patient data
- Competitive historical trial data
- Proprietary site network data
- Electronic medical and health records (EMR/HER) and claims platforms
Strategic Site Collaborations
Recognizing that identifying the right sites and preparing them to enroll patients are two additional challenges faced by our industry, PPD continuously expands our site network relationships. These relationships are a key component in accelerating quality research and the foundation to fully support patient enrollment and engagement. Our therapeutically aligned and constantly expanding strategic partnerships with global site networks, facilitate easy study setup and execution.
Our key site relationships include:
- Optimal Research
- PPD's global Phase I site network
- PPD® Select
- PPD's early phase oncology network (EPON)
- PPD's pediatric investigator network
Global Site Intelligence and Activation
Delays of any kind can have a negative impact on development, but few things are as critical as site activation when it comes to trial timelines and site relationships. PPD works to improve cycle times by harmonizing and planning startup activities across global study sites. Our best-in-class approach employs the sophisticated analytics of Preclarus®, our real-time data and analytics solution, to give operational teams cross-functional visibility to activate sites on time. Preclarus delivers analytics to manage site selection and study startup activities.
We’re able to streamline operational processes to optimize cycle times using a technology-enabled approach to site selection and activation. Enrollment rates further strengthen our approach. Our global site intelligence and activation services allow you to:
- Streamline the site selection process with historical reference sets/analysis to inform future opportunities and strategies
- Develop a statistically driven risk-prediction and escalation model that will accurately and reliably predict site activation and patient enrollment rates
- Provide transparency and accountability of forecasts, as well as a mechanism to course correct when deviating from targets
Patient Centricity and Innovation
Because we believe patients are the heart of clinical research, we strive to bring their views into the study design process earlier. Engaging and empowering clinical research participants, study sites and their caregivers improve retention in studies and research outcomes. Technology provides an avenue for making trials more convenient for sites and patients, as well as more efficient our clients. But we’ve also integrated patient-centric capabilities to bring the trial closer to the patient.
Through ongoing partnerships and innovative pilots, PPD is developing new clinical trial models that encourage study participation and reduce research burdens on patients and sites. Based on the goals of each study, we explore and advance designs aimed at delivering products to market faster and more efficiently, with a focus on expanding decentralized trial capabilities and the use of mobile platforms.